Evidence map›Paper›PMID 32640243›Full record

ArticleCell metabolism2020

SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure.

Ashish Verma, Ankit B Patel, Sushrut S Waikar

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Impact of SGLT2 inhibitors in cardiac amyloidosis: A systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Hemodynamics in Left-Sided Cardiomyopathies.Reviews in cardiovascular medicine · 2024
    Review
  12. Review
  13. Review
  14. The Role of Oxidative Stress in Kidney Injury.Antioxidants (Basel, Switzerland) · 2023
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ashish VermaRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: averma8@bwh.harvard.edu.
Ankit B PatelRenal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Sushrut S WaikarSection of Nephrology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown impressive cardiovascular health benefits in individuals treated with SGLT2 inhibitors (SGLT2i) regardless of diabetic status. The underlying mechanisms driving these benefits are not well understood. Recently in Circulation, Griffin et al. (2020) reported the first human study investigating the diuretic effect of empagliflozin.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsDiureticsGlucosidesHumansBenzhydryl CompoundsDiureticsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32640243

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.